Use of Infliximab for the Treatment of Pemphigus Vulgaris
NCT ID: NCT00283712
Last Updated: 2017-12-06
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
20 participants
INTERVENTIONAL
2006-03-31
2011-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This study will last 26 weeks. At study entry, all patients will be taking a stable dose of prednisone (or an equivalent corticosteroid) of 20 to 120 mg/day for at least 2 weeks prior to study entry. Patients will be randomly assigned to one of two arms: experimental or placebo comparator. The experimental treatment arm will receive infusions of infliximab, and the control arm will receive placebo. Infusions will be given at study entry and Weeks 2, 6, and 14. Before the start of each infusion, a physical exam, vital signs measurement, medical and medication history, review of a disease activity log, a skin evaluation, and blood collection will occur. During each infusion and for 1 hour postinfusion, patients' vital signs will be monitored for any adverse events. Patients will need a responsible adult to take them home after they are discharged from the treatment facility; this person should remain with the patient overnight in case any problems arise from the treatment. The patient will be contacted by phone that night and the next morning after infusion and will be asked about any adverse effects they may have experienced. Those patients that experience adverse effects may be asked to return to the treatment facility for examination. Prednisone doses may be tapered by 15 percent every 2 weeks during the study at the investigator's discretion.
There will be a total of 9 study visits until Week 26: screening, study entry, Week 2, and every 4 weeks thereafter. Each study visit will include a physical exam, vital signs measurement, medical and medication history, a review of the disease activity log and adverse events experienced since the last visit, skin assessments, and blood collection; patients will also be asked to complete a tuberculosis (TB) questionnaire. Patients will be asked to complete quality of life questionnaires at study entry and Weeks 10, 18, and 26. Skin biopsies of unaffected skin will be done at study entry and Weeks 10, 18, and 26; if patients have PV-associated lesions, additional skin biopsies of affected skin will be done at study entry and Week 18.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Infliximab
Participants are randomized to receive intravenous infusions of infliximab (5mg/kg reconstituted in 10 mL of Sterile Water for Injection, USP ) at Weeks 0, 2, 6, and 14 over a time period of no less than two hours in a masked (blinded) fashion. Refer to section titled, "Detailed Description" for additional treatment information.
Infliximab
Chimeric IgG monoclonal antibody that binds to TNF-alpha, generally used to treat Crohn's disease, given in a dosage of 5 mg/kg
Placebo Comparator
Participants are randomized to receive intravenous infusions of placebo (5 mg/kg comprised of a white lyophilized powder reconstituted in 10 mL of Sterile Water for Injection, USP) at Weeks 0, 2, 6, and 14 over a time period of no less than two hours in a masked (blinded) fashion. Refer to section titled, "Detailed Description" for additional treatment information.
Placebo Comparator
Placebo administered in place of infliximab for control group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Infliximab
Chimeric IgG monoclonal antibody that binds to TNF-alpha, generally used to treat Crohn's disease, given in a dosage of 5 mg/kg
Placebo Comparator
Placebo administered in place of infliximab for control group
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Failure to completely respond to standard steroid therapy (equivalent to prednisone 1 to 2 mg/kg/day followed by tapering)
* Systemic corticosteroid therapy of at least 20 mg prednisone daily and no more than 120 mg/day
* Inability to reduce systemic corticosteroid dosage below 20 mg/day for at least 8 weeks
* Stable dosage of prednisone for at least 2 weeks prior to study entry
* Oral/mucosal disease or skin disease. Detailed information about this criterion can be found in the protocol
* Willing to comply with the study protocol
* Willing to use acceptable means of contraception for the duration of the study and for 6 months after the end of the study
Exclusion Criteria
* History of latent or active TB prior to screening
* Signs or symptoms suggestive of TB disease by medical history or physical examination within 3 months prior to first administration of study drug
* Posterior/anterior/lateral chest radiograph within 3 months prior to screening showing evidence of cancer, infection, or abnormalities (apical scarring) suggestive of previous TB
* Serious infection, hospitalization for an infection, or treatment with intravenous (IV) antibiotics for an infection within 2 months prior to screening. Patients who have had less serious infections are eligible for this study at the discretion of the investigator.
* History or presence of opportunistic infections within 6 months prior to screening
* History of receiving human/murine recombinant products
* Known allergy to murine products or other chimeric proteins
* Human immunodeficiency virus (HIV) infected
* Chronic hepatitis B or hepatitis C virus infection
* History of hepatitis C virus infection
* Cancer within the 5 years prior to study entry. Patients with completely resected non-melanoma skin cancers are not excluded.
* History or presence of congestive heart failure
* History or presence of seizure or demyelinating disorder
* History of latent or active granulomatous infection, including TB, histoplasmosis, or coccidioidomycosis
* Received a Bacillus Calmette-Guerin (BCG) vaccine within 12 months of screening
* History of lymphoproliferative disease, including lymphoma or signs and symptoms of possible lymphoproliferative disease, such as lymphadenopathy of unusual size or location or enlarged spleen
* Current signs or symptoms of severe progressive or uncontrolled kidney, liver, blood, gastrointestinal, endocrine, lung, heart, neurologic, or cerebral disease
* Have had chronic or recurrent infectious disease including, but not limited to, chronic kidney infection, chronic chest infection, sinusitis, recurrent urinary tract infection, infected skin wound, or ulcer
* Previous treatment with infliximab, other monoclonal antibodies, or antibody fragments
* Previous treatment with etanercept or other anti-tumor necrosis factor (TNF) agents in the 3 months prior to screening
* Treatment with methotrexate, azathioprine, mycophenolate mofetil, plasmapheresis, IV immunoglobulin, pulse systemic corticosteroids, or other systemic immunosuppressive agents within the 4 weeks prior to study entry
* History of alcohol or drug abuse within the 3 years prior to study entry
* History of noncompliance to medical regimens
* History of a systemic inflammatory disease other than pemphigus vulgaris
* History of a medical condition that would interfere with participation or increase the risk to the participant
* Unable or unwilling to undergo blood draws because of poor tolerability or lack of easy access
* Use of any investigational drug within 30 days prior to screening OR within 5 half-lives of the investigational agent, whichever is longer
* Participation in another investigative clinical trial
* Presence of transplanted solid organ. Participants who have received a corneal transplant more than 3 months prior to screening are not excluded.
* Require certain medications
* Other conditions or circumstances that could interfere with participant's adherence to the study requirements
* Pregnancy, breastfeeding, or plans to become pregnant
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Autoimmunity Centers of Excellence
OTHER
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Russell P. Hall, MD
Role: STUDY_CHAIR
Division of Dermatology, Duke University Medical Center
E. William St. Clair, MD
Role: STUDY_CHAIR
Division of Rheumatology and Immunology, Duke University Medical Center
Garnett Kelsoe, DSci
Role: PRINCIPAL_INVESTIGATOR
Department of Immunology, Duke University
Victoria Werth, MD
Role: PRINCIPAL_INVESTIGATOR
Department of Dermatology, University of Pennsylvania School of Medicine
Janet Fairley, MD
Role: PRINCIPAL_INVESTIGATOR
Department of Dermatology, University of Iowa
David Woodley, MD
Role: PRINCIPAL_INVESTIGATOR
Department of Dermatology, Norris Cancer Center, University of Southern California
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Norris Cancer Center, University of Southern California
Los Angeles, California, United States
University of Iowa Hospitals and Clinics
Iowa City, Iowa, United States
Duke University Medical Center
Durham, North Carolina, United States
University of Pennsylvania
Philadelphia, Pennsylvania, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Anhalt GJ, Diaz LA. Pemphigus vulgaris--a model for cutaneous autoimmunity. J Am Acad Dermatol. 2004 Jul;51(1 Suppl):S20-1. doi: 10.1016/j.jaad.2004.01.011. No abstract available.
Drosou A, Kirsner RS, Welsh E, Sullivan TP, Kerdel FA. Use of infliximab, an anti-tumor necrosis alpha antibody, for inflammatory dermatoses. J Cutan Med Surg. 2003 Sep-Oct;7(5):382-6. doi: 10.1007/s10227-002-0134-1. Epub 2003 Sep 24.
Jacobi A, Shuler G, Hertl M. Rapid control of therapy-refractory pemphigus vulgaris by treatment with the tumour necrosis factor-alpha inhibitor infliximab. Br J Dermatol. 2005 Aug;153(2):448-9. doi: 10.1111/j.1365-2133.2005.06744.x. No abstract available.
Pardo J, Mercader P, Mahiques L, Sanchez-Carazo JL, Oliver V, Fortea JM. Infliximab in the management of severe pemphigus vulgaris. Br J Dermatol. 2005 Jul;153(1):222-3. doi: 10.1111/j.1365-2133.2005.06672.x. No abstract available.
Hall RP 3rd, Fairley J, Woodley D, Werth VP, Hannah D, Streilein RD, McKillip J, Okawa J, Rose M, Keyes-Elstein LL, Pinckney A, Overington A, Wedgwood J, Ding L, Welch B. A multicentre randomized trial of the treatment of patients with pemphigus vulgaris with infliximab and prednisone compared with prednisone alone. Br J Dermatol. 2015 Mar;172(3):760-8. doi: 10.1111/bjd.13350. Epub 2015 Feb 5.
Related Links
Access external resources that provide additional context or updates about the study.
National Institute of Allergy and Infectious Diseases (NIAID)
Division of Allergy, Immunology, and Transplantation (DAIT)
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DAIT APV01
Identifier Type: -
Identifier Source: org_study_id